Compare LEGH & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEGH | OMER |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 528.7M | 772.8M |
| IPO Year | 2018 | 2008 |
| Metric | LEGH | OMER |
|---|---|---|
| Price | $22.09 | $12.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $25.00 | ★ $32.50 |
| AVG Volume (30 Days) | 63.0K | ★ 1.2M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | 0.46 | ★ 0.62 |
| Revenue | ★ $164,567,000.00 | $29,868,000.00 |
| Revenue This Year | $11.90 | N/A |
| Revenue Next Year | $6.58 | $233.22 |
| P/E Ratio | $49.17 | ★ $21.46 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.29 | $2.95 |
| 52 Week High | $29.45 | $17.65 |
| Indicator | LEGH | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 53.09 | 37.56 |
| Support Level | $20.53 | $10.82 |
| Resistance Level | $22.46 | $13.00 |
| Average True Range (ATR) | 1.01 | 0.74 |
| MACD | 0.05 | -0.31 |
| Stochastic Oscillator | 49.41 | 11.65 |
Legacy Housing Corp builds, sells, and finances manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores, and are also sold directly to manufactured home communities. The Company manufactures and provides for the transport of manufactured homes, provides wholesale financing to dealers and mobile home parks, provides retail financing to consumers, and is involved in financing and developing new manufactured home communities. The Company manufactures its mobile homes at plants in Fort Worth, Texas; Commerce, Texas; and Eatonton, Georgia. The Company also sells homes directly to consumers, through its own retail stores, and to dealers and mobile home parks.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.